John A. Beutler, Ph.D.
Dr. Beutler has identified several natural products which have potential for development as cancer drugs, among them, englerins, which are in preclinical development for kidney cancer and Ewing’s sarcoma, schweinfurthins, which are preclinical candidates in glioblastoma and malignant peripheral nerve sheath tumors, and salicylihalamides, of interest in sarcomas. As a Staff Scientist 2, Dr. Beutler oversees the Program's high-throughput screening libraries, information technology, and drug development efforts.
1) natural products chemistry, 2) high-throughput screening, 3) molecular pharmacology
We are advancing two natural product projects towards the clinic: englerins for kidney cancer and Ewings sarcoma, and schweinfurthins for central nervous system (CNS) tumors and other NF1-dependent conditions. These natural products both have unique mechanisms of action. In addition, our group builds and maintains the library of chemical diversity with which the Molecular Targets Program conducts high-throughput screening campaigns based on CCR-identified molecular targets.
Selected Key Publications
- Bioorg Med Chem Lett. 26: 2641, 2016. [ Journal Article ]
- ChemMedChem. 11: 1003, 2016. [ Journal Article ]
Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality.Cancer Cell. 23: 228-37, 2013. [ Journal Article ]
Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.Mol Cancer Ther. 9: 1234-43, 2010. [ Journal Article ]
- Org Lett. 11: 57-60, 2009. [ Journal Article ]
B.A., Chemistry, Vassar College, 1972
M.Sc., Philadelphia College of Pharmacy & Science, 1978
Ph.D., Philadelphia College of Pharmacy & Science, 1980
Northeastern University, 1980-1
Assistant Professor, Auburn University School of Pharmacy, 1981-1983
University of Texas Medical School at Houston, 1983-4
AAAS Fellow, 2019
|Dongdong Wang Ph.D.||Postdoctoral Fellow (Visiting)|
|Dayani Sarath Parakumge Ph.D.||Postdoctoral Fellow (Visiting)|
|Fatma Memnune Erucar||Guest Researcher|
|Cheryl Thomas B.S.||Research Chemist|
|Ekaterina I. Goncharova Ph.D.||Programmer Analyst IV (Contr.)|
|Christopher Wolcott Ph.D.||IT Manager (Contr.)|
Currently a University of Maryland undergrad.
currently at Glaxo Smith Kline, New Providence, PA
Investigation of plants from the Brazilian cerrado for anticancer properties.
Professor at University of Brasilia.
Research for Ph.D. on cytotoxic principles of geopropolis from Brazilian stingless bee Melipona scutellaris.
Completed Ph.D. and currently a scientist at Brazliian Biosciences National Lab.
Current status: Associate Professor, Chonnam National University, Gwangju, Korea
formerly with Kingston lab, Virginia Tech
Current position: Virginia CommonWelath University Medical School
Research on Szechuan pepper alkamides as potential anticancer agents.
Currently a scientist at Albany Molecular Research Inc.
Isolation and structure elucidation of englerins.
Currently an Assistant Scientist in the Luesch lab at the University of Florida.
Carving pumpkins at our section get together.
Shaking hands with Steve Chu at AAAS Fellow reception in Seattle, pre-COVID.